The US FDA had conducted an inspection at the company's oncology (injectable and oral solid) formulation facility from 7 October 2024 to 8 October 2024.
"The inspection was successfully completed without any Form 483 observation," the company said in a statement.
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of pharmaceutical products, i.e. formulations and active pharmaceutical ingredients.
The pharmaceutical company’s consolidated net profit increased 11.69% to Rs 134.71 crore in Q1 FY25 as compared to Rs 120.60 crore posted in Q1 FY24. Revenue from operations grew 5.09% year on year (YoY) to Rs 1,561.73 crore in the quarter ended 30 June 2024.